HighPoint Advisor Group LLC Decreases Stock Position in Pfizer Inc. $PFE

HighPoint Advisor Group LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 28.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 169,565 shares of the biopharmaceutical company’s stock after selling 67,040 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Pfizer were worth $4,321,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. Shell Asset Management Co. boosted its holdings in Pfizer by 61.6% in the 2nd quarter. Shell Asset Management Co. now owns 89,658 shares of the biopharmaceutical company’s stock worth $2,173,000 after buying an additional 34,178 shares during the last quarter. Canopy Partners LLC increased its stake in Pfizer by 5.9% during the 2nd quarter. Canopy Partners LLC now owns 36,618 shares of the biopharmaceutical company’s stock worth $888,000 after buying an additional 2,024 shares in the last quarter. Finally, BankPlus Trust Department raised its holdings in shares of Pfizer by 11.7% during the second quarter. BankPlus Trust Department now owns 64,219 shares of the biopharmaceutical company’s stock valued at $1,557,000 after acquiring an additional 6,748 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

Pfizer Stock Performance

Shares of PFE stock opened at $26.83 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market cap of $152.55 billion, a P/E ratio of 19.73 and a beta of 0.47. The firm’s 50 day moving average price is $25.57 and its 200-day moving average price is $25.07. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.